Introduction: The European Medicines Agency (EMA) is the central EU body that coordinates scientific evaluation, supervision and safety monitoring of human medicines. For B.Pharm students, understanding EMA functions and approvals is essential: committees like CHMP, PRAC, COMP and PDCO set scientific standards; systems such as the centralized procedure, conditional authorisation, orphan designation and PRIME accelerate access; and databases like EudraVigilance support pharmacovigilance. Knowledge of marketing authorisation pathways, risk management plans (RMPs), scientific advice and post‑authorisation safety studies will strengthen regulatory competency. This set of focused, keyword‑rich MCQs covers EMA roles, committees, procedures and real regulatory scenarios to build practical exam readiness. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What is the primary role of the European Medicines Agency (EMA)?
- To coordinate evaluation, supervision and safety monitoring of medicines across the EU
- To manufacture medicines for EU countries
- To set drug prices across the EU
- To replace national competent authorities for clinical trials
Correct Answer: To coordinate evaluation, supervision and safety monitoring of medicines across the EU
Q2. Which procedure results in a single EU-wide marketing authorisation valid in all Member States?
- Mutual recognition procedure
- Decentralised procedure
- Centralised procedure
- National procedure
Correct Answer: Centralised procedure
Q3. Which EMA committee is primarily responsible for issuing scientific opinions on human medicines?
- PRAC (Pharmacovigilance Risk Assessment Committee)
- CHMP (Committee for Medicinal Products for Human Use)
- COMP (Committee for Orphan Medicinal Products)
- CAT (Committee for Advanced Therapies)
Correct Answer: CHMP (Committee for Medicinal Products for Human Use)
Q4. Which EMA committee leads on safety monitoring and pharmacovigilance for human medicines?
- PDCO (Paediatric Committee)
- COMP (Committee for Orphan Medicinal Products)
- PRAC (Pharmacovigilance Risk Assessment Committee)
- CAT (Committee for Advanced Therapies)
Correct Answer: PRAC (Pharmacovigilance Risk Assessment Committee)
Q5. Which committee handles orphan designation assessments at the EMA?
- CHMP
- COMP
- PRAC
- PDCO
Correct Answer: COMP
Q6. What is the role of the Paediatric Committee (PDCO)?
- To evaluate pharmacovigilance signals
- To assess paediatric investigation plans and advise on paediatric development
- To designate orphan medicinal products
- To manufacture paediatric medicines
Correct Answer: To assess paediatric investigation plans and advise on paediatric development
Q7. Which EMA committee evaluates advanced-therapy medicinal products (gene, cell and tissue therapies)?
- PDCO
- CAT
- COMP
- PRAC
Correct Answer: CAT
Q8. Which database is used by EMA and Member States to collect and analyse suspected adverse drug reactions?
- EudraCT
- EudraVigilance
- EudraGMDP
- ELM (European Licensing Module)
Correct Answer: EudraVigilance
Q9. Which types of products are typically evaluated through the centralized procedure?
- Local generic medicines only
- Biotechnology-derived medicines, advanced-therapy products and medicines for certain serious diseases (e.g., cancer, HIV)
- Over-the-counter herbal products only
- National traditional medicines
Correct Answer: Biotechnology-derived medicines, advanced-therapy products and medicines for certain serious diseases (e.g., cancer, HIV)
Q10. What is the EMA’s role regarding authorization of clinical trials in the EU?
- The EMA directly issues national clinical trial authorisations
- The EMA manufactures investigational products
- The EMA provides scientific guidance while national competent authorities authorise trials
- The EMA funds clinical trials across Member States
Correct Answer: The EMA provides scientific guidance while national competent authorities authorise trials
Q11. What is the PRIME scheme at EMA designed to do?
- Provide free manufacturing facilities
- Support development of medicines that target unmet medical needs and accelerate assessment
- Ensure all medicines are priced equally in the EU
- Replace the centralised procedure
Correct Answer: Support development of medicines that target unmet medical needs and accelerate assessment
Q12. What is the purpose of a conditional marketing authorisation?
- To authorise medicines without any data
- To allow early approval when immediate data are incomplete but benefits outweigh risks, with obligations to provide more data post-authorisation
- To grant permanent authorisation without renewal
- To provide authorisation only in the country of origin
Correct Answer: To allow early approval when immediate data are incomplete but benefits outweigh risks, with obligations to provide more data post-authorisation
Q13. How long is an EU marketing authorisation usually valid before renewal?
- 1 year
- 5 years
- 10 years
- Unlimited validity without renewal
Correct Answer: 5 years
Q14. One key criterion for orphan designation in the EU is:
- Annual prevalence of the condition is more than 1 in 1,000
- Annual prevalence of the condition is not more than 5 in 10,000 in the EU
- The medicine has completed Phase III trials
- The product is priced above a threshold
Correct Answer: Annual prevalence of the condition is not more than 5 in 10,000 in the EU
Q15. Which body coordinates mutual recognition and decentralized procedures among Member States?
- EMA Executive Director
- CMDh (Co‑ordination Group for Mutual Recognition and Decentralised Procedures – Human)
- World Health Organization (WHO)
- European Parliament Committee on Health
Correct Answer: CMDh (Co‑ordination Group for Mutual Recognition and Decentralised Procedures – Human)
Q16. After the CHMP issues a positive opinion, which institution gives the legally binding marketing authorisation decision for the EU?
- European Commission
- European Parliament
- World Health Organization
- National competent authority of the applicant’s country
Correct Answer: European Commission
Q17. Which document describes the plan to monitor and minimise important risks of a medicine after authorisation?
- Clinical Study Report (CSR)
- Risk Management Plan (RMP)
- SmPC (Summary of Product Characteristics)
- Investigational Medicinal Product Dossier (IMPD)
Correct Answer: Risk Management Plan (RMP)
Q18. Who can request scientific advice from the EMA?
- Only national regulators
- Medicine developers or sponsors (applicants)
- Only patients and patient groups
- Only the European Commission
Correct Answer: Medicine developers or sponsors (applicants)
Q19. What is the purpose of a referral procedure at EMA?
- To refer medicines to clinical trials outside the EU
- To resolve safety, efficacy or supply issues of major interest or disagreements between Member States
- To transfer marketing authorisations between companies
- To register traditional herbal medicines only
Correct Answer: To resolve safety, efficacy or supply issues of major interest or disagreements between Member States
Q20. What is EudraCT?
- A pharmacovigilance signal detection tool
- The EU clinical trials database that stores trial information for interventional clinical studies
- The EMA internal email system
- A marketing authorisation application form
Correct Answer: The EU clinical trials database that stores trial information for interventional clinical studies
Q21. Which regulation governs the centralised authorisation procedure at the EU level?
- Regulation (EC) No 726/2004
- Directive 2010/84/EU
- Regulation (EU) 2019/6
- Directive 2001/83/EC only
Correct Answer: Regulation (EC) No 726/2004
Q22. How is the CHMP composed?
- Only EMA staff scientists
- Experts nominated by each EU Member State plus co-opted experts when needed
- Representatives of pharmaceutical companies
- Members of the European Parliament
Correct Answer: Experts nominated by each EU Member State plus co-opted experts when needed
Q23. What are post-authorisation safety studies (PASS)?
- Studies to evaluate manufacturing processes only
- Safety studies conducted after authorisation to monitor risks in real‑world use
- Preclinical toxicology studies
- Price negotiation assessments
Correct Answer: Safety studies conducted after authorisation to monitor risks in real‑world use
Q24. How does EMA contribute to the quality standards of medicines?
- By developing and issuing scientific guidelines and assessing quality data during authorisation
- By producing active pharmaceutical ingredients
- By setting retail pharmacy procedures
- By directly inspecting every manufacturing site worldwide
Correct Answer: By developing and issuing scientific guidelines and assessing quality data during authorisation
Q25. What is a marketing authorisation under exceptional circumstances?
- An authorisation granted when comprehensive data cannot be obtained but the medicine meets unmet needs with conditions on ongoing data collection
- An authorisation that never requires pharmacovigilance
- An authorisation only for veterinary medicines
- A temporary import waiver
Correct Answer: An authorisation granted when comprehensive data cannot be obtained but the medicine meets unmet needs with conditions on ongoing data collection
Q26. Which EMA policy promotes publication of clinical data and regulatory documents to increase transparency?
- Good Manufacturing Practice (GMP) policy
- EMA transparency policy on clinical data and regulatory decision-making
- Patent protection policy
- Confidentiality-only policy
Correct Answer: EMA transparency policy on clinical data and regulatory decision-making
Q27. What is one incentive provided to developers of orphan medicinal products in the EU?
- Extended market exclusivity for a period after authorisation
- Automatic full reimbursement by all Member States
- Guaranteed higher pricing without assessment
- Exemption from all post-authorisation studies
Correct Answer: Extended market exclusivity for a period after authorisation
Q28. Is a marketing authorisation granted via the centralised procedure valid across all EU Member States?
- No, it is valid only in the authorising Member State
- Yes, it is valid across the entire EU
- Yes, but only for five named Member States
- No, it must be converted into national licences
Correct Answer: Yes, it is valid across the entire EU
Q29. Which mechanism is used to shorten the review time of a marketing-authorisation application for medicines of major public health interest?
- Standard assessment only
- Accelerated assessment procedure
- Voluntary national delay
- Conditional clinical trial pause
Correct Answer: Accelerated assessment procedure
Q30. Who enforces pharmacovigilance obligations and inspections at national level within the EU?
- Individual sponsors only
- National competent authorities of Member States
- World Trade Organization
- European Central Bank
Correct Answer: National competent authorities of Member States
